In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...
While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...
Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker ...
Just Arsenal on MSN
Barcelona will be a serious challenger to Arsenal for young Dutchman | OneFootball
Arsenal have a history of recruiting Dutch players, both in the past and in the present. Within the current squad, Jurrien ...
Researchers discovered that clogged brain “drains” show up early in people at risk of Alzheimer’s disease. These blockages, ...
TipRanks on MSN
InflaRx Reveals Phase 3 Post‑Hoc Efficacy Signals for Vilobelimab in Pyoderma Gangrenosum After Trial Halt
On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma gangrenosum (PG), a rare, difficult-to-treat ulcerative skin disease, following the trial’s early ...
Discover Lulutox Detox Tea, a herbal blend designed to support digestion, detox balance, and daily wellness. Ingredients, ...
The Manila Times on MSN
From retail shelf space to screen space
FOR many micro, small and medium-sized enterprises (MSMEs), the biggest challenge today is no longer product quality or consumer demand. It is access.
Singapore has one of the highest life expectancies in the world, yet many individuals spend almost a decade in poor health ...
Zacks Investment Research on MSN
Omeros gets FDA approval for YARTEMLEA as first therapy for TA-TMA
Omeros Corporation OMER recently announced that the FDA approved its YARTEMLEA (narsoplimab-wuug) to treat hematopoietic stem ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback